Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lomibuvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomibuvir SCHEMBL15893235 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| Lomibuvir SCHEMBL101462 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| Lomibuvir SCHEMBL17856953 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| Lomibuvir SCHEMBL15960458 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| Lomibuvir SCHEMBL134631 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| SCHEMBL12949713 | 0.97 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL15233239 | 0.97 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL15498203 | 0.97 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL15498324 | 0.97 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL12433104 | 0.95 | NR1I2 (0.63) | NR1I2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2559691-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | claimed |
| EP-2559692-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | claimed |
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-11-29 | — | — | US | claimed |
| US-8269014-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-09-18 | — | — | US | claimed |
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals ( Canada) Incorporated (CA) | 2012-03-08 | — | — | US | claimed |
| EP-2104674-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2009-09-30 | — | — | EP | claimed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | claimed |
| WO-2008058393-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2008-05-22 | — | — | WO | claimed |
| WO-2017062840-A1 | COMBINATION THERAPY FOR THE TREATMENT OF HEPATITIS C VIRUS | TREK THERAPEUTICS, PBC (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017062840-A1 | COMBINATION THERAPY FOR THE TREATMENT OF HEPATITIS C VIRUS | TREK THERAPEUTICS, PBC (US) | 2017-04-13 | — | — | WO | disclosed |
| US-9296719-B2 | Compositions and methods for the treatment of norovirus infection | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296719-B2 | Compositions and methods for the treatment of norovirus infection | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2507249-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-11-11 | — | — | EP | disclosed |
| WO-2015072247-A1 | CANCER STEM CELL-TARGETING DRUG COMPOSITION | 独立行政法人国立がん研究センター | 2015-05-21 | — | — | WO | disclosed |
| WO-2012130862-A1 | SELECTION OF HCV TREATMENT | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-04 | — | — | WO | disclosed |
| US-8269014-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-09-18 | — | — | US | disclosed |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals ( Canada) Incorporated (CA) | 2012-03-08 | — | — | US | disclosed |
| US-8003685-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2011-08-23 | — | — | US | disclosed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885CYP2E1 6/4885 |
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885CYP2E1 98/4885 |
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885CYP2E1 98/4885 |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885CYP2E1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.